Regulatory Compliance for AI in Life Sciences

What Every Pharma Leader Needs to Know About AI in Life Sciences and Following the Rules

In the life sciences, compliance is not a goal; it is the starting point. Regulators are paying more attention as AI becomes a strategic tool in the pharmaceutical, biotech, and medical technology industries.

AI systems are powering everything from making content to improving trials, from medical affairs to clinical ops.

But every digital leader should ask this question:

“Is it possible to grow AI without putting our ability to follow the rules, our reputation, or our license to do business at risk?”

This blog explains the rules that govern AI in the life sciences, points out the risks to avoid, and gives a framework for using AI in a safe, ethical, and auditable way.

1. Regulators are not ignoring AI; they are changing with it.

People think that the FDA and EMA don’t say anything about AI, but they are actually making the rules.

The FDA includes AI in the Software as a Medical Device (SaMD) framework, giving a rough idea of how to manage the lifecycle of machine learning.

Focuses on monitoring after deployment, being open, and controlling risk

EMA puts data integrity, traceability, and human oversight first.

Supports explainability and documentation as important parts of AI governance

There are still new rules coming out for GenAI, but the expectations are clear:

• Record how the model acts
• Use systems that have people in the loop (HITL)
• Use standards for risk-based validation

2. GxP Rules Still Apply. AI Is Not Exempt.

GxP rules still apply to AI in medical information, pharmacovigilance, and research and development.

What this means for AI systems:

• Every step must be recorded, given a time stamp, and linked to a person.
• Keep up good documentation practices (GDP)
• There must be a clear difference between decisions made with AI and those made by people.

For every action that AI affects, use identity tags and audit trails.

3. AI Validation: It’s not about being perfect; it’s about setting limits.

Regulatory validation doesn’t mean proving your model is perfect; it means making sure:

• The system works within acceptable limits that have been set.
• There are clear records of inputs, outputs, and risk thresholds.
• We find and test edge cases and ways that things can go wrong.

Think of GenAI workflows as hybrid systems and check the process, not just the algorithm.

4. You Have to Keep an Eye on Model Drift Now

Model drift is when the performance of AI changes over time.

Regulators want companies to:

• Check the accuracy of the output on a regular basis
• Keep records of retraining and version updates
• Keep track of changes in performance over time

Tools like MLflow, custom dashboards, or proprietary monitoring systems can make this process automatic.

5. Explainability and Source Traceability Are Required

Not only do life sciences need accuracy, they also need clarity. 

Your AI outputs need to be:

• Can be traced back to approved content sources
• With an explanation of how the result was reached
• Versioned, with a clear path of data

Retrieval-Augmented Generation (RAG) is a promising way to base GenAI outputs on data that can be checked.

6. Design for Respect for Privacy and Data Ethics

• AI systems must follow strict rules about data privacy:
• HIPAA (US): Keeps patient information safe in clinical systems
• GDPR (EU): Needs permission, limits data collection, and gives people the right to be forgotten
• 21 CFR Part 11: Deals with electronic signatures and records
• Don’t ever put Personally Identifiable Information (PII) into open models unless you are in a secure, approved environment.

7. There is no way to avoid human oversight

There shouldn’t be any AI systems in life sciences that run themselves. Make sure:

• Review by a person in the loop (HITL) at important decision points
• Set up override workflows for important tasks
• SOPs that make it clear who is responsible for decisions made by AI
• Teach users how to check AI outputs, point out mistakes, and step in when necessary.

8. Internal audits are how you stay compliant. Lifeline

AI should be treated the same way as any other regulated digital system. 

That means:

• Regular reviews of readiness and internal audits
• Getting Quality and Compliance teams involved early
• Keeping records of user feedback, problems, and version changes
• Doing practice audits to see how ready you are for an audit

9. Check out your vendors. Some of them aren’t ready for compliance.

A lot of AI vendors build quickly. Fewer people build for pharma.

Say:

• Experience with GxP validation
• Documents for the government
• Ability to help with audit defence

Even better, partner with companies like Newpage that build compliance into every AI deployment, from prompt tuning to model monitoring.

Last but not least: move quickly, but do it safely. Pharma isn’t here to slow down progress. It’s here to make things safe, dependable, and responsible.

Artificial intelligence is here to stay. The companies that do well won’t be the ones that move the fastest; they’ll be the ones that find a balance between speed and structure.

We help life sciences teams make AI systems that are compliant, traceable, and ready for audits. These systems are trusted by regulators, healthcare professionals, and our own teams.

Let’s talk about how to build your next AI deployment the right way, the first time.